Section Arrow
CLRB.NASDAQ
- Cellectar Biosciences
(Financial Status)
Quotes are at least 15-min delayed:2025/05/31 19:55 EDT
Last
 0.255
-0.009 (-3.41%)
Day High 
0.265 
Prev. Close
0.264 
1-M High
0.28 
Volume 
213.88K 
Bid
0.2515
Ask
0.2645
Day Low
0.248 
Open
0.265 
1-M Low
0.23 
Market Cap 
12.17M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.25 
20-SMA 0.25 
50-SMA 0.29 
52-W High 3.42 
52-W Low 0.224 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.63/-0.63
Enterprise Value
12.57M
Balance Sheet
Book Value Per Share
0.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/05/31 19:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.